Company news

Enveric Biosciences, Inc. news in 2022

Enveric Biosciences, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Enveric Biosciences Announces Confidential Submission of Registration Statement for the Spin-off of its Cannabinoid Business to Shareholders

November 27, 2022

Enveric Biosciences Announces Poster Presentations of Lead Programs at the 2022 International Neurology & Brain Disorders Conference

October 11, 2022

Enveric Biosciences Appoints New Independent Directors

July 26, 2022

Enveric Biosciences Announces Closing of $8 Million Registered Direct and Private Placement Offerings, Priced at a Premium to Market Under Nasdaq Rules

July 25, 2022

Enveric Biosciences Announces $8 Million Registered Direct Offering and Private Placement, Priced at a Premium to Market Under Nasdaq Rules

July 24, 2022

Enveric Biosciences Announces Formation of Scientific Advisory Board to Drive Further Growth of Next-Generation Mental Health Medicines

July 18, 2022

Enveric Biosciences Announces Plans to Spin-off and Dividend its Cannabinoid Pipeline to Shareholders

May 10, 2022

Enveric Biosciences Announces Distribution of Series C Preferred Stock to Holders of its Common Stock

May 2, 2022

Enveric Biosciences Reports Full-Year 2021 Financial Results and Provides Business Update

March 30, 2022

Enveric Biosciences Expands Portfolio of Drug Development Candidates and Files New Provisional Patent Application

March 28, 2022

Enveric Biosciences Announces Publication of Four Patent Applications for Psychedelic-Inspired Drug Candidates

March 14, 2022

Enveric Biosciences Announces Closing of $10 Million Public Offering

February 14, 2022

Enveric Biosciences Announces Pricing of $10 Million Public Offering

February 10, 2022

Enveric Biosciences Announces Proposed Public Offering

February 9, 2022

Enveric Biosciences Announces Successful Synthesis and Filing of Provisional Patent for EV104 - Cannabinoid + Celecoxib Conjugate

February 7, 2022

Decks in 2022